Medication
5 Minutes

GLP-1 side effects: what can you expect with Ozempic, Wegovy, Saxenda and Mounjaro?

GLP-1 side effects: what can you expect?
Written by
Goodweigh Team
Reviewed by
Last change
13 November 2026
https://www.goodweigh.nl/blog/glp-1-side-effects

Medically reviewed by Dr. Jaramillo, a doctor at Goodweigh. Last updated on 6 October 2026

Short answer from Dr. Jaramillo

Most people mainly experience nausea, diarrhoea, vomiting, constipation and abdominal pain. These symptoms usually occur at the start of treatment and at higher doses, and then subside. Serious side effects are rare, but have been reported with semaglutide, liraglutide and tirzepatide: acute pancreatitis and diabetic retinopathy or changes in vision. Contact a doctor immediately if you have severe, persistent abdominal pain (which may radiate to your back).

Dr. Jaramillo, doctor at Goodweigh

Want to find out more? Start your intake here

Ozempic, Wegovy, Saxenda and Mounjaro work in similar ways, so their side effects are very similar. Ozempic and Wegovy contain semaglutide (Ozempic is authorised for type 2 diabetes), Saxenda contains liraglutide and Mounjaro contains tirzepatide.

Why do GLP-1 agents cause similar side effects?

The drugs are similar because they work in much the same way. Semaglutide and liraglutide mimic GLP-1, a hormone produced in your gut. Tirzepatide does the same and also mimics a second gut hormone, GIP, as described in a review article in Diabetes Care.

All three active ingredients slow down gastric emptying and act on the central appetite control system, leading to a greater feeling of fullness. This delayed gastric emptying is a key driver of weight loss. The Farmacotherapeutisch Kompas lists this as a side effect of semaglutide, liraglutide and tirzepatide.

The most common GLP-1 side effects

The most common side effects are gastrointestinal symptoms. According to the Farmacotherapeutisch Kompas, more than 1 in 10 users of semaglutide, liraglutide and tirzepatide experience nausea, vomiting, diarrhoea or constipation. In the case of semaglutide and tirzepatide, this also applies to abdominal pain.

A review of 26 studies involving over 15,000 adults without diabetes revealed the same pattern: mainly gastrointestinal symptoms. Few people stopped taking the medication due to side effects, and serious side effects were rare.

With Wegovy, nearly half of the participants experienced nausea, about a third had diarrhoea and about a quarter vomited, more frequently than with a placebo.

With Mounjaro, nausea, vomiting and diarrhoea were more common as the dose was increased, and these symptoms diminished over time. Among those without diabetes, around a quarter to a third of people experienced nausea, depending on the dose, much more frequently than with a placebo.

If you are vomiting or have diarrhoea, drink extra fluids to prevent dehydration, especially if you have kidney problems. If you are unable to do so, contact your doctor. Read more in the article on nausea caused by GLP-1 medication and in the guide on what to eat whilst taking GLP-1 medication.

What serious GLP-1 side effects should you be aware of?

The most significant of these are pancreatitis, dehydration which can affect the kidneys, gallstones and a severe allergic reaction. They are less common than gastrointestinal symptoms, but have been reported in all three cases.

Acute pancreatitis (a sudden inflammation of the pancreas) occurred in approximately 1 in 500 people taking Wegovy, slightly more frequently than with a placebo. However, this was not the case in people with cardiovascular disease. The warning sign is severe, persistent pain in the abdominal region, sometimes radiating to the back. If this is suspected, treatment is stopped.

Persistent vomiting or diarrhoea can cause your body to become dehydrated, which may lead to your kidneys not functioning as well. The package leaflets for Saxenda and Mounjaro also mention acute kidney failure, which means that your kidneys suddenly stop functioning properly.

Gallstones and cholecystitis occur in all three. With Wegovy, gallstones were reported in 1.6 per cent of people taking semaglutide, and cholecystitis in 0.6 per cent.

A severe allergic reaction is a rare side effect of semaglutide, liraglutide and tirzepatide. Cases of intestinal obstruction, a serious form of constipation, have also been reported with semaglutide and liraglutide.

If you are due to have a general anaesthetic, please inform the medical staff in advance that you are taking this medicine. There have been cases where stomach contents have entered the lungs whilst taking Mounjaro.

Research based on day-to-day practice frequently identified gastrointestinal complaints. It did not reveal a clear increase in serious conditions such as pancreatitis, pancreatic cancer, thyroid disorders or depression.

How do the different GLP-1 medicines differ from one another?

The differences are minor: most side effects occur with all three. Studies on tirzepatide show that the side effects are similar to those of drugs that only mimic GLP-1. These mainly include nausea, vomiting, diarrhoea and constipation, which are more common at higher doses. These studies were conducted in people with type 2 diabetes.

An increased heart rate occurs with all three, according to the patient information leaflets for Wegovy, Mounjaro and Saxenda. On average, this amounts to 3 beats per minute for semaglutide and tirzepatide, and 2.5 for liraglutide.

Hair loss was reported in 2.5 per cent of semaglutide users. This occurred more frequently than with a placebo, and even more frequently in cases of weight loss of 20 per cent or more. For tirzepatide, hair loss is also listed as a common side effect in the Kompas.

NAION, a very rare eye condition, is listed for all medicines containing semaglutide. You’ll find this information for Ozempic, Wegovy and Rybelsus. For Wegovy, this equates to approximately 1 additional case per 10,000 people treated for one year, based on data from adults with type 2 diabetes.

Cutaneous amyloidosis (a build-up of protein under the skin at the injection site) has only been reported with Saxenda (liraglutide). You should therefore always vary the injection site.

The table shows how common a side effect is, according to Kompas and, for Rybelsus, the product information leaflet itself. ‘Very common’ means in more than one in ten people, and ‘very rare’ means in fewer than one in ten thousand people. The figures for Rybelsus are taken from studies on type 2 diabetes.

Side effect Wegovy (semaglutide) Saxenda (liraglutide) Mounjaro (tirzepatide) Rybelsus (semaglutide tablet)
Nausea very common very common very common very common
Vomiting very common very common very common common
Diarrhoea very common very common very common very common
Constipation very common very common very common common
Gallstones common common uncommon uncommon
Hair loss common not stated common not stated
Acute pancreatitis uncommon uncommon uncommon rare
NAION very rare not stated not stated very rare


‍
The figures are taken from various studies and are not directly comparable.

Read more about the side effects of semaglutide, the side effects of Ozempic, the side effects of Wegovy, the side effects of tirzepatide (Mounjaro) and the side effects of Saxenda. See also: Wegovy, Mounjaro and Saxenda compared.

Do GLP-1 tablets have different side effects to the injections?

No, the tablets mainly cause the same stomach and gut problems as the injections. Rybelsus contains semaglutide in tablet form and is only authorised for type 2 diabetes. With Rybelsus, approximately one in seven people experienced nausea, one in ten had diarrhoea and one in fourteen vomited. These side effects were more common at the higher doses of 25 and 50 mg.

After taking it, wait at least 30 minutes before eating, drinking or taking any other medicines.

Regarding the Wegovy tablets for weight management, the European Medicines Agency (EMA) reports that gastrointestinal complaints were the most common side effects. The safety profile appeared to be similar to that of the weekly Wegovy injection. Read more about the Wegovy tablet (oral semaglutide) and a comparison of oral and injectable semaglutide.

Does the pill still work if you’re taking GLP-1 medication?

This is expected to be the case with semaglutide and liraglutide. With Mounjaro, our doctors recommend taking extra precautions. For Wegovy, Rybelsus and Saxenda, it is stated that semaglutide and liraglutide do not reduce the effectiveness of the pill to any extent that would be clinically significant. This also applies to a single dose of tirzepatide, according to the European package leaflet for Mounjaro.

Our doctors do, however, recommend using a condom for 4 weeks after each dose increase with Mounjaro. The US package leaflet for tirzepatide also recommends this for 4 weeks after starting treatment, or the use of non-oral contraception. If you could become pregnant, you should use contraception during treatment. If you are planning to have a baby, you can read more in the section on Ozempic during pregnancy and when planning a pregnancy.

When should you contact your doctor?

Contact your doctor immediately if you experience severe pain in the stomach area that does not subside and may radiate to your back. You should also do so if you have persistent vomiting or diarrhoea causing dehydration, or if you suddenly lose your sight or your vision rapidly deteriorates. You should also contact your doctor if you have severe pain in the top right-hand side of your abdomen (possibly gallstones) or if you have severe constipation accompanied by abdominal pain and vomiting.

Seek medical help immediately if you experience any signs of a severe allergic reaction, such as difficulty breathing or rapid swelling of the face or throat. If in doubt, or if you experience palpitations whilst at rest or symptoms that significantly interfere with your daily life, always contact your doctor.

Taking insulin or certain diabetes tablets alongside Wegovy increases the risk of low blood sugar. Our doctors therefore do not combine GLP-1 medication with these medicines. You can also report any side effects yourself to Lareb, the side-effects reporting centre.

How does Goodweigh support you if you experience side effects?

With Goodweigh, you gradually increase the dose; with Wegovy and Mounjaro, this takes 16 to 20 weeks, and a doctor monitors your symptoms. The dose is increased in accordance with the patient information leaflet to minimise stomach and bowel problems. Our doctors also use this approach to prevent excessive weight loss.

Every four weeks, you’ll fill in an evaluation form about side effects and how the treatment is working, which a doctor will review each time your dose is increased. In the meantime, you can ask questions via the chat. You can read more about how it works.

Side effects are usually predictable and temporary

Nausea, vomiting and diarrhoea are most common when the dose is first increased and then decrease significantly. Make sure you recognise the signs of serious side effects.

Quellen

Moiz, A., Filion, K. B., Toutounchi, H., Tsoukas, M. A., Yu, O. H. Y., Peters, T. M., & Eisenberg, M. J. (2025). Efficacy and safety of glucagon-like peptide-1 receptor agonists for weight loss among adults without diabetes: A systematic review of randomized controlled trials. Annals of Internal Medicine, 178(2), 199-217. https://pubmed.ncbi.nlm.nih.gov/39761578/

Gorgojo-Martínez, J. J., Mezquita-Raya, P., Carretero-Gómez, J., Castro, A., Cebrián-Cuenca, A., de Torres-Sánchez, A., García-de-Lucas, M. D., Núñez, J., Obaya, J. C., Soler, M. J., Górriz, J. L., & Rubio-Herrera, M. Á. (2022). Clinical recommendations to manage gastrointestinal adverse events in patients treated with GLP-1 receptor agonists: A multidisciplinary expert consensus. Journal of Clinical Medicine, 12(1), 145. https://pubmed.ncbi.nlm.nih.gov/36614945/

Drucker, D. J. (2024). Efficacy and safety of GLP-1 medicines for type 2 diabetes and obesity. Diabetes Care, 47(11), 1873-1888. https://pubmed.ncbi.nlm.nih.gov/38843460/

Nauck, M. A., & D'Alessio, D. A. (2022). Tirzepatide, a dual GIP/GLP-1 receptor co-agonist for the treatment of type 2 diabetes with unmatched effectiveness regrading glycaemic control and body weight reduction. Cardiovascular Diabetology, 21(1), 169. https://pubmed.ncbi.nlm.nih.gov/36050763/

Thomsen, R. W., Mailhac, A., Løhde, J. B., & Pottegård, A. (2025). Real-world evidence on the utilization, clinical and comparative effectiveness, and adverse effects of newer GLP-1RA-based weight-loss therapies. Diabetes, Obesity and Metabolism, 27(Suppl 2), 66-88. https://pubmed.ncbi.nlm.nih.gov/40196933/

Farmacotherapeutisch Kompas. Semaglutide. https://www.farmacotherapeutischkompas.nl/bladeren/preparaatteksten/s/semaglutide

Farmacotherapeutisch Kompas. Liraglutide. https://www.farmacotherapeutischkompas.nl/bladeren/preparaatteksten/l/liraglutide

Farmacotherapeutisch Kompas. Tirzepatide. https://www.farmacotherapeutischkompas.nl/bladeren/preparaatteksten/t/tirzepatide

European Medicines Agency. Wegovy: productinformatie. https://www.ema.europa.eu/nl/documents/product-information/wegovy-epar-product-information_nl.pdf

European Medicines Agency. Saxenda: productinformatie. https://www.ema.europa.eu/nl/documents/product-information/saxenda-epar-product-information_nl.pdf

European Medicines Agency. Mounjaro: productinformatie. https://www.ema.europa.eu/nl/documents/product-information/mounjaro-epar-product-information_nl.pdf

European Medicines Agency. Ozempic: productinformatie. https://www.ema.europa.eu/nl/documents/product-information/ozempic-epar-product-information_nl.pdf

European Medicines Agency. Rybelsus: productinformatie. https://www.ema.europa.eu/nl/documents/product-information/rybelsus-epar-product-information_nl.pdf

European Medicines Agency. (2026). First oral GLP-1 treatment for weight management. https://www.ema.europa.eu/en/news/first-oral-glp-1-treatment-weight-management

European Medicines Agency. (2024). Meeting highlights from the Pharmacovigilance Risk Assessment Committee (PRAC) 8-11 April 2024. https://www.ema.europa.eu/en/news/meeting-highlights-pharmacovigilance-risk-assessment-committee-prac-8-11-april-2024

European Medicines Agency. (2023). Meeting highlights from the Pharmacovigilance Risk Assessment Committee (PRAC) 23-26 October 2023. https://www.ema.europa.eu/en/news/meeting-highlights-pharmacovigilance-risk-assessment-committee-prac-23-26-october-2023

U.S. National Library of Medicine. DailyMed: Zepbound (tirzepatide), prescribing information. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=487cd7e7-434c-4925-99fa-aa80b1cc776b

U.S. National Library of Medicine. DailyMed: Wegovy (semaglutide), prescribing information. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ee06186f-2aa3-4990-a760-757579d8f77b

‍

Frequently Asked Questions

How long do the side effects of GLP-1 medication last?

Stomach and bowel complaints mainly occur at the start of treatment and when the dose is increased. They then usually subside within a few days to weeks.In the studies with Wegovy, nausea lasted for less than 8 days in half of the participants. Diarrhoea lasted for less than 3 days in half of the participants.For half of the patients, the constipation lasted less than 47 days. If your symptoms persist or get worse, please speak to your doctor.

Which GLP-1 medication has the fewest side effects?

There is no clear-cut answer to this. Semaglutide, liraglutide and tirzepatide mainly cause the same gastrointestinal symptoms, and direct comparisons are largely lacking. A few side effects are associated with only one of the drugs. NAION, a very rare eye condition, is listed only for semaglutide, whilst skin amyloidosis at the injection site is listed only for liraglutide.

Do GLP-1 medications increase the risk of suicidal thoughts or thyroid cancer?

The European Medicines Agency (EMA) found no causal link with suicidal thoughts or self-harm, or with thyroid cancer. This applied to, amongst others, semaglutide and liraglutide. Tirzepatide was not included in that study.The US package leaflet for Wegovy does, however, warn of thyroid tumours. In the European patient information leaflets, these are listed only as findings in rodents. If you or a family member has MEN2 (a hereditary condition) or a rare form of thyroid cancer (medullary), our doctors will not prescribe it. Read also about Ozempic and depression.

Can I take GLP-1 medication if I’m having a general anaesthetic?

Please let them know in advance that you are taking this medicine. GLP-1 medication slows down the emptying of your stomach. There have been reports of stomach contents entering the lungs during anaesthesia or deep sedation. Your doctor and the anaesthetist can then take this into account.

Are GLP-1 medicines harmful to your pancreas?

Acute pancreatitis has been reported with all three medicines, but is rare: in the studies on semaglutide, it occurred in approximately 1 in 500 users. Severe, persistent pain in the stomach area that may radiate to the back is a reason to contact a doctor immediately.